XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
C
C

Cigna


Actualités

U.S. AMC Networks, Permian Resources, Vital Energy

U.S. RESEARCH ROUNDUP-AMC Networks, Permian Resources, Vital Energy May 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMC Networks, Permian Resources and Vital Energy, on Monday. HIGHLIGHTS * AMC Networks AMCX.O : Moffettnathanson cuts target price by $1 to $13 * Celanese Corp CE.N : Jefferies raises target price to $170 from $155 * Permian Resources Corp PR.N : Gerdes Energy Research raises to buy from neutral
A
B
C
G
H
A
A
A
U
A
A
C

Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates

CORRECTED-UPDATE 2-Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates Corrects in paragraph 6 to say Cigna and Optum are covering two or three Humira biosimilars By Steven Scheer JERUSALEM, May 8 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said it was set to launch its long awaited biosimilar of AbbVie's ABBV.N blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. The drugmaker also said late-stage results
C
T

U.S. Berkshire Hathaway, Parker-Hannifin, Quaker Houghton

U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Parker-Hannifin, Quaker Houghton May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Berkshire Hathaway, Parker-Hannifin and Quaker Houghton, on Monday. HIGHLIGHTS * Berkshire Hathaway BRKa.N : KBW raises target price to $660,000 from $645,000 * Essex Property Trust Inc ESS.N : Piper Sandler raises target price to $315 from $291 * Parker-Hannifin Corp PH.N : Jefferies cuts
A
C
E
G
E
C
C

U.S. Paramount Global, Sprout Social, Williams-Sonoma

U.S. RESEARCH ROUNDUP- Paramount Global, Sprout Social, Williams-Sonoma May 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Paramount Global, Sprout Social and Williams-Sonoma ,on Friday. HIGHLIGHTS * Expedia Group Inc EXPE.O : Piper Sandler cuts to neutral from overweight * Paramount Global PARA.O : Seaport Research Partners cuts to neutral from buy * Sprout Social Inc SPT.O : Piper Sandler cuts to neutral from ov
A
A
B
B
C
E
F
H
S
D
T
B
Z
A
B
C
M
T

Cigna Says Regulatory Review By U.S. DOJ Of Medicare Business Sale Is Complete

BRIEF-Cigna Says Regulatory Review By U.S. DOJ Of Medicare Business Sale Is Complete May 2 (Reuters) - Cigna Group CI.N : CIGNA EXEC SAYS REGULATORY REVIEW BY THE US DOJ OF CO'S DEAL TO SELL MEDICARE BUSINESS TO HEALTH CARE SERVICE CORP IS COMPLETE - CONF CALL CIGNA EXEC SAYS CO SAW "SOME DISRUPTION TO CLAIM SUBMISSIONS AND PAYMENTS" IN Q1 DUE TO C
C

Cigna Group reports results for the quarter ended in March - Earnings Summary

Cigna Group reports results for the quarter ended in March - Earnings Summary Cigna Group CI.N reported quarterly adjusted earnings of $6.47​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $5.41. The mean expectation of twenty two analysts for the quarter was for earnings of $6.22 per share.
C

Cigna lifts annual profit view on lower medical costs, pharmacy benefit strength

UPDATE 2-Cigna lifts annual profit view on lower medical costs, pharmacy benefit strength Adds analyst comment in paragraph 5, change cyberattack details in paragraphs 8 and 9 By Bhanvi Satija May 2 (Reuters) - Cigna Group CI.N raised its annual profit forecast on Thursday, helped by lower-than-expected medical costs and strength in its pharmacy benefit management unit.
C

Fed QT taper calms the horses, yen pops again

MORNING BID AMERICAS-Fed QT taper calms the horses, yen pops again A look at the day ahead in U.S. and global markets from Mike Dolan Anxious bond traders seem to have taken solace from the Federal Reserve's surprisingly sharp brake on its "quantitative tightening" process on Wednesday, while the yen capitalized on an easier dollar after what seemed like the second bout of Japanese intervention this week.
A
A
A
C
E
H
I
R
S
U
A
U
I
V
W
Z
A
B
D
H
I
L
P
P
P
T

Cigna sees strong annual profit on lower costs, pharmacy benefit strength

Cigna sees strong annual profit on lower costs, pharmacy benefit strength May 2 (Reuters) - Health insurer Cigna Group CI.N raised its annual profit forecast on Thursday, as lower-than-expected medical costs and strength in its pharmacy benefit management unit helped it beat first-quarter earnings estimates. The company now expects an adjusted profit of at least $28.40 per share in 2024, up 15 cents from its previous forecast.
C

What to Watch in the Day Ahead - Thursday, May 2

What to Watch in the Day Ahead - Thursday, May 2 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple's revenue is expected to decline 5% and would mark the fifth instance of topline drop in the past six quarters as demand for its chief commodity the iPhone as well Mac computers remains weak.
A
A
C
E
I
K
R
C
B
W
A
L
P
P

Cigna Group <CI.N> expected to post earnings of $6.22 a share - Earnings Preview

Cigna Group expected to post earnings of $6.22 a share - Earnings Preview Cigna Group CI.N , CI is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2024 The Bloomfield Connecticut-based company is expected to report a 21.6% increase in revenue to $56.517 billion from $46.48 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data.
C

Drugmaker AbbVie expects Humira volume erosion to worsen

UPDATE 4-Drugmaker AbbVie expects Humira volume erosion to worsen Adds analyst comment in paragraph 7, background on Cigna's Humira plans in paragraph 6, updates shares By Leroy Leo and Christy Santhosh April 26 (Reuters) - AbbVie ABBV.N expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs.
C

Cigna to offer Humira rivals with $0 copay at specialty pharmacy

Cigna to offer Humira rivals with $0 copay at specialty pharmacy By Patrick Wingrove and Amina Niasse April 25 (Reuters) - Cigna CI.N plans to make close copies of AbbVie's ABBV.N blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday.
C
N
T

The Cigna Group Declares Quarterly Dividend

BRIEF-The Cigna Group Declares Quarterly Dividend April 24 (Reuters) - Cigna Group CI.N : THE CIGNA GROUP DECLARES QUARTERLY DIVIDEND CIGNA GROUP - DECLARED A CASH DIVIDEND OF $1.40 PER SHARE OF ITS COMMON STOCK Source text for Eikon: ID:nPncbdzC1a Further company coverage: CI.N
C

U.S. STOCKS AZZ, Vanda Pharma, Matterport

BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks rose on Monday in choppy trading after steep losses in the previous session as easing Middle East tensions buoyed risk appetite, while investors looked ahead to an action-packed week with major tech earnings and a key inflation print.
C
M
N
S
T
V
Z
U
U
U

U.S. STOCKS AZZ, Smartsheet, Zions Bancorporation

BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Smartsheet, Zions Bancorporation Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Monday after steep losses in the previous session as easing Middle East tensions buoyed risk appetite, while investors looked ahead to an action-packed week with major tech earnings and a key inflation print.
C
N
S
T
V
Z
U
U
U

Jefferies says Cigna's Humana buyout 'plausible' at $420/share

BUZZ-Jefferies says Cigna's Humana buyout 'plausible' at $420/share ** Brokerage Jefferies says Humana's HUM.N acquisition by Cigna CI.N "seems plausible" for ~$420/share despite CI abandoning pursuit in Dec - a possible 26.5% premium to current share price ** HUM shares have fallen 32% since then till last close, with health insurers in general al
C

U.S. STOCKS Ibotta, Blackstone, US health insurers

BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes gained on Thursday as investors cheered upbeat earnings across several sectors, while advancing megacap growth stocks were amongst the biggest boosts.
C
D
T
L
U
U
U
E
A
E
G
S

U.S. STOCKS Ally Financial, Zscaler, Las Vegas Sands

BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The benchmark S&P 500 and the Nasdaq were subdued on Thursday as higher Treasury yields pressured equities, while investors digested commentary from Federal Reserve officials to ascertain the outlook for interest-rate cuts.
C
D
T
L
R
U
U
U
E
T
A
E
G
S

Elevance's Q1 profit beat lifts shares of US health insurers

BUZZ-Elevance's Q1 profit beat lifts shares of US health insurers ** Shares of U.S. health insurers rise between 1% and 4% after Elevance Health ELV.N posts upbeat Q1 profit ** Higher premiums from Elevance's commercial insurance plans helped keep company's medical costs in check ** ELV, which also slightly raises its annual earnings forecast , up 5.5% to $537 following results ** UnitedHealth UNH.N up 4.2%, Humana HUM.N gains 1.2%, Centene CNC.N rises about 3% ** Cigna Group CI.N stock rises ab
C



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.